AbbVie profit misses as Humira faces biosimilar challenge in Europe

AbbVie Inc on Friday posted a fourth-quarter profit that missed Wall Street estimates, as the drugmaker's top-selling drug, Humira, faces competition from cheaper rival versions in Europe.